Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Rating Increased to Strong-Buy at DZ Bank

DZ Bank upgraded shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) from a hold rating to a strong-buy rating in a report published on Tuesday morning,Zacks.com reports.

Other equities research analysts also recently issued research reports about the company. Zacks Research raised Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a report on Friday, May 8th. UBS Group raised Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a report on Monday, March 16th. Three research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy”.

Bayer Aktiengesellschaft Price Performance

Shares of OTCMKTS BAYRY opened at $11.34 on Tuesday. The company has a debt-to-equity ratio of 1.22, a quick ratio of 0.63 and a current ratio of 1.01. Bayer Aktiengesellschaft has a fifty-two week low of $6.69 and a fifty-two week high of $14.85. The company has a market cap of $44.57 billion, a PE ratio of -17.72, a P/E/G ratio of 3.52 and a beta of 0.62. The business has a 50-day simple moving average of $11.29 and a two-hundred day simple moving average of $11.07.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last released its earnings results on Tuesday, May 12th. The company reported $0.79 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.15. Bayer Aktiengesellschaft had a positive return on equity of 17.74% and a negative net margin of 4.75%.The firm had revenue of $15.73 billion during the quarter, compared to the consensus estimate of $15.77 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. As a group, equities analysts expect that Bayer Aktiengesellschaft will post 1.25 EPS for the current fiscal year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.